Whitepaper: What our remediation projects are saying about the industry

Based on a study of the pharma industry’s remediation projects, this white paper from NSF looks at the key issues behind GMP non-conformance. It also includes questions to ask yourself when making changes to your processes and systems.

“A study on the pharma industry’s GMPremediation projects reveals a lot about us and our inability to focus only on what is trulyvaluable,” says John Johnson.

NSF’s pharma team is in a unique position since we are regularly and intimately involved in a range of GMP remediation projects across the world and across all dosage forms. When a system or process fails to provide sufficient levels of quality assurance or inadequately maintains compliance to cGMP, the best case scenario is that your quality system identifies the issue and escalates it to the right people, and those people study the problem and apply the right resources to fix it now and for the future.